Our Blood-Based Prenatal Fetal DNA Testing Platform Development Project Has Been Selected
We are pleased to report that seeDNA Inc. (hereafter, "the Company") has had its "Blood-Based Prenatal Fetal DNA Testing Platform Development Project" selected for Adachi Ward's FY2020 "New Product and Business Development Subsidy."
The "New Product and Business Development Subsidy" is a program that supports businesses that develop or improve new products, technologies, and services and expand into new fields. Our "Blood-Based Prenatal Fetal DNA Testing Platform Development Project" was highly evaluated for being the world's first to develop a platform capable of performing prenatal fetal DNA testing using fetal DNA extracted from maternal blood, leading to this selection.
Encouraged by this selection, the Company will continue to advance research and development of DNA testing technology, striving to pursue greater accuracy and reliability in testing, in order to meet the needs of our customers.